Singapore markets closed

Repare Therapeutics Inc. (RPTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
12.19-0.14 (-1.14%)
At close: 04:00PM EDT
12.19 0.00 (0.00%)
After hours: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 519.02M
Enterprise value 242.88M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)3.10
Price/book (mrq)2.11
Enterprise value/revenue 1.46
Enterprise value/EBITDA 27.87

Trading information

Stock price history

Beta (5Y monthly) 0.02
52-week change 32.75%
S&P500 52-week change 317.24%
52-week high 318.68
52-week low 38.02
50-day moving average 310.02
200-day moving average 311.08

Share statistics

Avg vol (3-month) 396.55k
Avg vol (10-day) 3149.15k
Shares outstanding 542.09M
Implied shares outstanding 642.09M
Float 817.08M
% held by insiders 11.03%
% held by institutions 188.19%
Shares short (30 Aug 2023) 41.2M
Short ratio (30 Aug 2023) 413.11
Short % of float (30 Aug 2023) 44.83%
Short % of shares outstanding (30 Aug 2023) 42.86%
Shares short (prior month 30 Jul 2023) 41.23M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)29 Jun 2023


Profit margin -1.85%
Operating margin (ttm)4.10%

Management effectiveness

Return on assets (ttm)1.40%
Return on equity (ttm)-1.31%

Income statement

Revenue (ttm)166.67M
Revenue per share (ttm)3.97
Quarterly revenue growth (yoy)4,354.90%
Gross profit (ttm)15.11M
Net income avi to common (ttm)-3.08M
Diluted EPS (ttm)-0.07
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)280.69M
Total cash per share (mrq)6.67
Total debt (mrq)4.55M
Total debt/equity (mrq)1.85%
Current ratio (mrq)5.48
Book value per share (mrq)5.83

Cash flow statement

Operating cash flow (ttm)-7.61M
Levered free cash flow (ttm)38.63M